Compare Remitly Global Inc (RELY) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Remitly Global Inc vs 10X Genomics Inc — how do they compare? Remitly Global Inc trades at $23.6 (market cap $4.98B), while 10X Genomics Inc trades at $81.96 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2× Remitly Global Inc's market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 3,501,150). Which is the better fit depends on your goals — on Pluang, investors hold Remitly Global Inc for 53 Days and 10X Genomics Inc for 92 Days on average.
| RELY | TXG | |
|---|---|---|
Market Cap | $4.98B | $10.07B |
Volume | 3,501,150 | 5,657,286 |
Sector | Technology | Health |
52-Week High | $26.92 | $97.74 |
52-Week Low | $12.20 | $11.48 |
Typical Hold Time | 53 Days | 92 Days |
Enterprise Value | $4.34B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with Q2 2026 revenue growth of 20% to $495 million and three consecutive quarterly EPS beats. Analyst consensus is strongly bullish with a $30.50 price target, supported by expanding profit margins and active customer growth exceeding 10 million.
Outlook remains positive given robust revenue growth and profitability expansion, but risks include competitive pressures in fintech and reliance on continued customer acquisition. The stock offers upside to analyst targets, though volatility may persist amid market shifts.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
